Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-28 23:15:52 阅读(143)
Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Sensex surges 500 pts, Nifty trades above 17800 in early trade on Wednesday, Feb 1; Coal India, ACC shares fall
- After short breather; FPIs invest in equities on global uncertainty, concerns over China
- Alternative investment funds under Sebi lens as growth gathers pace; Assets up 42% so far this year
- Sebi to auction properties of Saradha Group of Companies on Dec 16
- Adani Green Energy, Adani Transmission among 174 BSE stocks to touch 52-week lows, 74 stocks hit 52-week highs
- Sebi returns OYO’s draft IPO papers; asks to refile with updates
- 6 key themes to help India’s corporate earnings beat emerging markets; check preferred sector stocks to buy
- Sebi’s SCORES platform disposes of 3,010 complaints in November; receives 2,886 new plaints
- 90% of generative AI pilot projects may not make it to production in 2024